Every 8-K that OrthoPediatrics Corp. (KIDS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow KIDS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KIDS filings page.
OrthoPediatrics Corp., a company focused exclusively on pediatric orthopedics, presents an investor update highlighting a $6.2B global addressable market and a strategy centered on child-specific implants, a broad product portfolio, global sales coverage and extensive clinical education for pediatric orthopedic surgeons.
The company reports steady revenue expansion, with 2025 revenue of $236.3 million versus $204.7 million in 2024, and 2Q 2026 revenue of $70.5 million compared with $61.1 million in 2Q 2025. Despite growth, OrthoPediatrics continues to post net losses, including a 2025 diluted EPS of $(1.69).
Management provides 2026 guidance for revenue of $265.0–$269.0 million, Adjusted EBITDA of approximately $25.0 million and roughly breakeven free cash flow. As of June 30, 2026, the balance sheet shows $47.9 million in cash and short-term investments and $99.6 million of debt. The presentation also outlines a multi-year “super-cycle” of differentiated pediatric product launches and explains non-GAAP measures such as Adjusted EBITDA, adjusted diluted loss per share and free cash flow used in assessing operating performance.
OrthoPediatrics Corp. reported record second-quarter 2026 net revenue of $70.5 million, up 15% from $61.1 million a year earlier, driven by 26% growth in Trauma and Deformity products and 22% international revenue growth. U.S. revenue was $54.8 million and international revenue $15.7 million. Gross profit rose to $52.4 million with margin improving to 74% from 72%.
Adjusted EBITDA reached a record $6.8 million versus $4.1 million in 2025, while net loss was $7.2 million, or $0.30 per share, similar to the prior year. Free cash flow usage in the quarter improved to $3.1 million from $13.9 million. The company raised full-year 2026 revenue guidance to $265.0–$269.0 million, reiterated expected adjusted EBITDA of about $25.0 million, and continues to target breakeven free cash flow in 2026.
OrthoPediatrics Corp. reported the results of its 2026 Annual Meeting of Stockholders held on June 4, 2026. Stockholders elected four directors – George S. M. Dyer, Kelly Fischer, David R. Pelizzon, and Harald Ruf – for terms running until the 2029 annual meeting.
Stockholders approved, on an advisory basis, the compensation of the company’s named executive officers with 15,953,457 votes for, 2,859,793 against, and 39,764 abstentions, plus 1,827,535 broker non-votes. They also approved an amendment to the 2024 Incentive Award Plan to add 2,050,000 shares, bringing the total shares authorized under the plan to 3,679,000.
In addition, stockholders approved the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 20,479,183 votes for, 154,131 against, and 47,235 abstentions.
OrthoPediatrics Corp. furnished an investor presentation outlining recent performance and 2026 outlook. The company reported 2025 revenue of $236.3 million, up from $204.7 million in 2024, with a net loss of $39.6 million and diluted EPS of ($1.69). First-quarter 2026 revenue was $59.4 million versus $52.4 million a year earlier, while Adjusted EBITDA improved to $2.2 million from a slight loss. The business continues to post strong growth in trauma, deformity and scoliosis product families, supported by more than 85 pediatric systems and broad global distribution. As of March 31, 2026, the company held $50.9 million in cash, cash equivalents and short-term investments. For 2026, management guides revenue to $263.0–$267.0 million, Adjusted EBITDA of about $25.0 million and free cash flow breakeven.
OrthoPediatrics Corp. reported strong first quarter 2026 results, combining double‑digit growth with improved profitability metrics. Revenue reached $59.4 million, up 13% from $52.4 million a year earlier, driven by 14% growth in Trauma & Deformity products and 13% growth in Scoliosis. U.S. revenue rose 11% to $45.3 million, while international revenue grew 22% to $14.1 million, with gross margin steady at 73%.
Operating loss narrowed to $8.3 million, and although net loss was $10.7 million, roughly flat year over year, adjusted EBITDA improved to a positive $2.2 million from a $0.4 million loss. Free cash flow usage improved to $5.0 million from $8.4 million, helped by higher adjusted EBITDA and better working capital. The company raised its 2026 revenue outlook to a range of $263.0 million to $267.0 million, implying 11% to 13% growth, and reiterated expectations for about $25.0 million of adjusted EBITDA and breakeven free cash flow for the full year.
OrthoPediatrics Corp. amended its existing term loan agreement to add a new delayed draw term loan facility of up to $20.0 million. Subject to conditions in the amendment, the company may draw this in minimum $10.0 million increments until June 30, 2027, allowing it to access capital as needed.
The facility carries interest at the SOFR Interest Rate with a 3.25% floor plus 6.50%, with an option for a 1.00% payment-in-kind component, and interest-only payments until the August 5, 2029 maturity. OrthoPediatrics will pay a 1.00% upfront fee and a 0.05% per annum delayed draw ticking fee, along with exit and prepayment fees consistent with the existing agreement.
OrthoPediatrics Corp. furnished an investor presentation outlining its 2025 performance and 2026 outlook. For 2025, revenue reached $236.3 million, up 15% from $204.7 million, with gross margin at 73%. The company still posted a net loss of $39.6 million, or $1.69 per diluted share, but delivered Adjusted EBITDA of $14.8 million and improved free cash flow to a $15 million outflow from $42 million the prior year.
The presentation highlights long-term double-digit revenue growth, a broad pediatric-focused product portfolio and contributions from acquisitions such as Boston Orthotics & Prosthetics. Management’s 2026 guidance targets revenue of $262.0 to $266.0 million, Adjusted EBITDA of about $25 million and breakeven free cash flow, emphasizing ongoing investment in new technologies and clinic expansion.
OrthoPediatrics Corp. reported strong growth for the fourth quarter and full year 2025 while remaining unprofitable overall. Full year revenue reached $236.3 million, up 15% from $204.7 million in 2024, with U.S. revenue of $186.4 million and international revenue of $49.9 million, both rising 15–16%.
Fourth quarter 2025 revenue was $61.6 million, up 17% year over year, and gross margin improved to 73.2%. Adjusted EBITDA grew to $4.8 million in the quarter and $14.8 million for the year, but the company still posted a 2025 net loss of $39.6 million, or $1.69 per share.
Cash and investments totaled $62.9 million as of December 31, 2025, and the company generated about $9.8 million of free cash flow in the fourth quarter, its first positive free cash flow quarter. For 2026, OrthoPediatrics projects revenue of $262.0–$266.0 million, adjusted EBITDA of $25.0 million, and breakeven free cash flow.
OrthoPediatrics Corp. filed a current report describing upcoming presentations by its executive officers to investors and analysts. The company has prepared an investor presentation that is included as Exhibit 99.1 and may be used, in whole or in part, during these meetings. The investor presentation and related information are being furnished under a Regulation FD disclosure item and are not considered filed for liability purposes under the Securities Exchange Act of 1934 or automatically incorporated into other securities law filings.
OrthoPediatrics Corp. furnished an update on its business by issuing a press release with preliminary unaudited net revenue and free cash flow for the fourth quarter and full year ended December 31, 2025. The company also provided management’s projection of 2026 net revenue and offered a related business update. These figures are described as preliminary estimates that remain subject to completion of the audit process and may change, and the company highlights that actual 2025 and 2026 net revenue could differ materially from the estimates and projections. The disclosure emphasizes that these statements are forward-looking and directs readers to previously disclosed risk factors for elements that could cause results to vary.
OrthoPediatrics Corp. (KIDS) furnished an investor presentation. The company’s executive officers plan upcoming presentations to investors and analysts and intend to use materials included as Exhibit 99.1, titled “OrthoPediatrics Corp. Investor Presentation” dated October 2025.
The materials are provided under Item 7.01 (Regulation FD) and are furnished, not filed, meaning they are not subject to liability under Section 18 of the Exchange Act and are not incorporated into other Securities Act or Exchange Act filings unless specifically referenced.
OrthoPediatrics Corp. furnished an 8-K announcing its earnings for the quarter ended September 30, 2025. The press release, including unaudited condensed consolidated financial statements and other financial data, is attached as Exhibit 99.1 and incorporated by reference.
The information under Item 2.02 is furnished and not deemed “filed” under Section 18 of the Exchange Act or incorporated by reference except as expressly set forth.
Orthopedics Corp (KIDS) disclosed that it has prepared preliminary net revenue estimates but these figures are subject to completion of the company's audit and may change. The company warns that results for the third quarter and for the full year could differ materially from the preliminary estimates and cautions readers not to place undue reliance on forward-looking statements. Investors are directed to the Risk Factors discussion in the company's Annual Report filed with the SEC for factors that could cause actual results to diverge. The company also states it will not update these forward-looking estimates publicly unless required by law.
OrthoPediatrics announced the Board accepted the resignation of director Terry Schlotterback due to retirement, effective August 8, 2025; the filing states the departure was not due to any disagreement with the Company. The Board appointed Kelly Fischer to fill the vacancy and to serve in the director class expiring at the annual stockholder meeting in 2026. Ms. Fischer has been Senior Vice President and Chief Financial Officer of Cook Medical since 2003 and will join the Board's Audit Committee and Compensation Committee.
For her service, Ms. Fischer will be eligible to receive a pro rata portion of the 2025 Award under the Company's Non-Employee Director Compensation Policy (described in Exhibit 10.1 to a recent Quarterly Report). The Board also agreed that the remaining 10,900 unvested restricted shares previously granted to Mr. Schlotterback will remain outstanding and continue to vest on their scheduled timelines as though he remained a director. The company disclosed no material plans, contracts or related-party transactions involving Ms. Fischer.